Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Background Bloodstream infections are associated with substantial morbidity and mortality. Early, appropriate antibiotic therapy is important, but the duration of treatment is uncertain. Methods In a multicenter, noninferiority trial, we randomly assigned hospitalized patients (including patients in the intensive care unit [ICU]) who had bloodstream infection to receive antibiotic treatment for 7 days or 14 days. Antibiotic selection, dosing, and route were at the discretion of the treating team. We excluded patients with severe immunosuppression, foci requiring prolonged treatment, single cultures with possible contaminants, or cultures yielding Staphylococcus aureus . The primary outcome was death from any cause by 90 days after diagnosis of the bloodstream infection, with a noninferiority margin of 4 percentage points. Research Summary Antibiotic Treatment for 7 or 14 Days for Bloodstream Infection Results Across 74 hospitals in seven countries, 3608 patients underwent randomization and were included in the intention-to-treat analysis; 1814 patients were assigned to 7 days of antibiotic treatment, and 1794 to 14 days. At enrollment, 55.0% of patients were in the ICU and 45.0% were on hospital wards. Infections were acquired in the community (75.4%), hospital wards (13.4%) and ICUs (11.2%). Bacteremia most commonly originated from the urinary tract (42.2%), abdomen (18.8%), lung (13.0%), vascular catheters (6.3%), and skin or soft tissue (5.2%). By 90 days, 261 patients (14.5%) receiving antibiotics for 7 days had died and 286 patients (16.1%) receiving antibiotics for 14 days had died (difference, −1.6 percentage points [95.7% confidence interval {CI}, −4.0 to 0.8]), which showed the noninferiority of the shorter treatment duration. Patients were treated for longer than the assigned duration in 23.1% of the patients in the 7-day group and in 10.7% of the patients in the 14-day group. A per-protocol analysis also showed noninferiority (difference, −2.0 percentage points [95% CI, −4.5 to 0.6]). These findings were generally consistent across secondary clinical outcomes and across prespecified subgroups defined according to patient, pathogen, and syndrome characteristics. Conclusions Among hospitalized patients with bloodstream infection, antibiotic treatment for 7 days was noninferior to treatment for 14 days. (Funded by the Canadian Institutes of Health Research and others; BALANCE ClinicalTrials.gov number, NCT03005145 .)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Biomarker-guided strategies, randomized trials of bloodstream infection duration, and recent meta-analyses have shown that less antibiotic exposure can be appropriate in selected patients when clinical stability and source control are present (24–29).”
From Day-4 antipseudomonal and anti-MRSA de-escalation was not associated with higher mortality in critically ill patients with sepsis (2026) · cites this paper as [26]
Citations
Cites
Moher, D., Hopewell, S., Schulz, K. F., Montori, V., Gotzsche, P. C., Devereaux, P. J., Elbourne, D., Egger, M., & Altman, D. G. (2010) · BMJ · doi:10.1136/bmj.c869 · Cited by 8,883
Ikuta, K. S., Swetschinski, L. R., Robles Aguilar, G., Sharara, F., Mestrovic, T., Gray, A. P., Davis Weaver, N., Wool, E. E., Han, C., Gershberg Hayoon, A., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)02185-7 · Cited by 2,235
Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by Staphylococcus aureus
Fowler, V. G., Boucher, H. W., Corey, G. R., Abrutyn, E., Karchmer, A. W., Rupp, M. E., Levine, D. P., Chambers, H. F., Tally, F. P., Vigliani, G. A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053783 · Cited by 1,459
Chastre, J., Wolff, M., Fagon, J.-Y., Chevret, S., Thomas, F., Wermert, D., Clementi, E., Gonzalez, J., Jusserand, D., Asfar, P., et al. (2003) · JAMA · doi:10.1001/jama.290.19.2588 · Cited by 1,376
Bouadma, L., Luyt, C.-E., Tubach, F., Cracco, C., Alvarez, A., Schwebel, C., Schortgen, F., Lasocki, S., Veber, B., Dehoux, M., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61879-1 · Cited by 1,183
Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis
Iversen, K., Ihlemann, N., Gill, S. U., Madsen, T., Elming, H., Jensen, K. T., Bruun, N. E., Høfsten, D. E., Fursted, K., Christensen, J. J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1808312 · Cited by 824
Association of adverse events with antibiotic use in hospitalized patients.
Tamma, P. D., Avdic, E., Li, D. X., Dzintars, K., & Cosgrove, S. E. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2017.1938 · Cited by 800
Goto, M., & Al-Hasan, M. N. (2013) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12195 · Cited by 752
Trial of short-course antimicrobial therapy for intraabdominal infection.
Sawyer, R. G., Claridge, J. A., Nathens, A. B., Rotstein, O. D., Duane, T. M., Evans, H. L., Cook, C. H., O’Neill, P. J., Mazuski, J. E., Askari, R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411162 · Cited by 747
Paul, M., Shani, V., Muchtar, E., Kariv, G., Robenshtok, E., & Leibovici, L. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00627-10 · Cited by 724
Cited by
Items 101–158 of 158
Chen, Y., Xie, M., Pei, Y., Ye, H., Lin, W., Kuang, W., Wu, X., & Xu, X. (2025) · Microporous and Mesoporous Materials · doi:10.1016/j.micromeso.2025.113917
Antibiotic Stewardship in der Hämatologie und Onkologie
Schalk, E., Vehreschild, J. J., Teschner, D., Schwanz, T., & Schmidt‐Hieber, M. (2025) · best practice onkologie · doi:10.1007/s11654-025-00699-0
Tverring, J., & Ong, S. W. X. (2025) · CMI Communications · doi:10.1016/j.cmicom.2025.105169
Duration of antibiotic therapy: with or without biomarkers?
Guerreiro, G., Fustiga, J., & Póvoa, P. M. S. R. (2026) · Acute and Critical Care · doi:10.4266/acc.002525 · Cited by 1
“The study found that the shorter course showed no inferiority in terms of mortality and relapse, suggesting that fixed durations might be sufficient in treating even serious infections [12].”
Lau, C. (2025) · Springer eBooks · doi:10.1007/978-3-032-10050-4_27
Fujimoto, N., Oi, I., Fujita, K., Yoshimura, S., Ito, T., Imakita, T., Kanai, O., & Tanizawa, K. (2026) · Respirology Case Reports · doi:10.1002/rcr2.70457
Characterizing the Use of High-Dose Amoxicillin for the Treatment of Bacteremia
Lloyd, J., Lau, K., San, C., Leung, V., & Lee, C. (2026) · Pathogens · doi:10.3390/pathogens15010054
Vijayasimha, M. (2026) · Die Anaesthesiologie · doi:10.1007/s00101-025-01633-3
Update on infection: from prevention to diagnosis and management
Nseir, S., Salluh, J. I. F., & Póvoa, P. M. S. R. (2026) · Intensive Care Medicine · doi:10.1007/s00134-025-08285-2
Kraft, B. D., & Despotovic, V. (2026) · American Journal of Respiratory and Critical Care Medicine · doi:10.1093/ajrccm/aamag071
Sun, S., Ding, M., Yan, B., Song, L., teng, G., Yu, X., Ning, Y., & Wang, C. (2026) · European journal of medical research · doi:10.1186/s40001-026-04103-7
Tate, T., Smith, B. J., Viehman, J. A., & Shields, R. K. (2026) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofag120
“Recently, the BALANCE trial [6] demonstrated that 7 days of antibiotic therapy was noninferior to 14 days of therapy in patients with BSI.”
Hojat, L., & Spivak, E. S. (2026) · Clinical Infectious Diseases · doi:10.1093/cid/ciag145
Antibiotic Stewardship for the Intensivist
Hawes, A. M., & Cosgrove, S. E. (2026) · Critical Care Clinics · doi:10.1016/j.ccc.2026.01.004
Bastow, C. R., Mei, C., Wen, S. W., Wilson, J. L., Nguyen, H., Suthya, A. R., Bourne, J. H., Lankadeva, Y. R., & Wong, C. H. Y. (2026) · Intensive Care Medicine Experimental · doi:10.1186/s40635-026-00886-5 · Cited by 1
Koutake, Y., Oishi, H., Nagasaki, Y., Yamada, M., Fujimoto, A., Soejima, K., Nishi, H., Adaniya, G., & Hayashi, T. (2026) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2026.102957
Umer, M., Jagra, A. S., Hanif, F. M., Khan, M., & Sharma, H. O. (2026) · Journal of Critical Care · doi:10.1016/j.jcrc.2026.155586
Cost savings of outpatient parenteral antimicrobial therapy using a digital infusion pump
Helleren, R., Jacobsen, M., Theisen, T., Moe, C. E., Opsal, A., Trønnes, R., Skogen, V., & Gallefoss, F. (2026) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlag052
Fralick, M., Stall, N. M., Zorcic, K., Reppas‐Rindlisbacher, C. E., Kaplovitch, E., Li, A. S., MacFadden, D. R., Kobewka, D. M., Castellani, L., Parsons, P., et al. (2026) · Journal of the American Geriatrics Society · doi:10.1111/jgs.70480
Zuccaro, V., Asperges, E., Marvulli, L. N., Valsecchi, P., Pagani, E., Sacchi, P., & Bruno, R. (2026) · Infection · doi:10.1007/s15010-026-02821-y
Shetty, A., & Shankar, M. (2026) · World Journal of Nephrology · doi:10.5527/wjn.118797
Leestemaker-Palmer, A., Nuss, S., & Bermudez, L. E. (2026) · Antibiotics · doi:10.3390/antibiotics15060593
“…by different pathogens are treated with single or a combination of antibiotics, and recent work has shown that for the most common infections, reducing the period of administration of an active antibiotic from 14 to 7 days can result in similar outcomes compared to much longer treatments [24].”
Cambiais, A. M. V. B., Pinto, V. B., Sforsin, A. C. P., Malbouisson, L. M. S., Lichtenstein, A., Luccia, N. D., Campos, A. F., Boszczowski, Í., Costa, S. F., & Guimarães, T. (2026) · Antimicrobial Resistance and Infection Control · doi:10.1186/s13756-026-01761-4
“In recent years, multiple randomized controlled trials have demonstrated that shorter treatment courses are non-inferior to traditional longer regimens for several infections, supporting antimicrobial stewardship strategies aimed at optimizing treatment duration [26, 29–32].”
Li, C., Schultze, M. D., Tedeschi, C., Rock, A. E., Gillett, E. M., Letourneau, A. R., & Wu, T. (2026) · Antimicrobial Stewardship & Healthcare Epidemiology · doi:10.1017/ash.2026.10746
Schmidt, J. B., Nielsen, K. L., Strunin, D., Kirkby, N. S., Thomassen, J. Q., Rasmussen, S. C., Frikke‐Schmidt, R., Hertz, F. B., & Engsig‐Karup, A. P. (2026) · BMJ Digital Health & AI · doi:10.1136/bmjdh-2026-000068 · Cited by 1
Кryvoruchko, І. А., Sartelli, M., Coccolini, F., Catena, F., & Habeeb, T. A. A. M. (2026) · The Ukrainian Journal of Clinical Surgery · doi:10.26779/2786-832x.2026.3.104
Reinhold, I., Sprute, R., Stemler, J., & Cornely, O. A. (2026) · CMI Communications · doi:10.1016/j.cmicom.2026.105211
Forestier, E., Soudais, B., Caspar, Y., Etienne, M., Milacic, H., Orcel, V., Baudron, C. R., Vallée, M., Dinh, A., & Lafaurie, M. (2026) · Infectious Diseases Now · doi:10.1016/j.idnow.2026.105319 · Cited by 2
Procalcitonin—An Enigmatic Anxiolytic Biomarker
Spellberg, B. J. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.20978
Jones, J., Colven, R. B., Morrisette, T., Hornback, K. M., Deloney, L. P., Gruss, Z. P., Alvira-Arill, G. R., Delay, T. A., & Hamby, A. (2026) · Antimicrobial Stewardship & Healthcare Epidemiology · doi:10.1017/ash.2026.10771
“34 37 Though few patients experienced intolerance to SMX-TMP, it is unclear if a re-evaluation would yield the same primary outcomes in a cohort whose course was more aligned with a seven-day duration.”
Çınar, C., Çaycı, Y. T., Atakcan, Z., BIYIK, İ., Bılgın, K., Vural, D. G., & Bırıncı, A. (2026) · Polish Journal of Microbiology · doi:10.33073/pjm-2026-020
Kumar, R. N. (2026) · Current Infectious Disease Reports · doi:10.1007/s11908-026-00889-z
Wang, X., Wu, J., Shen, C., Tian, R., Dai, Y., Huang, J. Y., Zhong, D.-E., Fang, D., Sun, J., Qu, H., et al. (2026) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2026.1850336
“Notably, many existing studies on bloodstream infections systematically exclude immunocompromised patients, persistent bacteremia, polymicrobial infections, and drug-resistant pathogens (Papp et al., 2023; Lee et al., 2025; The BALANCE Investigators, 2025).”
Carpenter, S. L., & Coopersmith, C. M. (2026) · Springer eBooks · doi:10.1007/978-3-032-22660-0_26
Rodríguez-Urbistondo, C., & Cisneros, J. M. (2026) · Medicina Clínica · doi:10.1016/j.medcli.2026.107537
Protecting the Gut Microbiome When Treating Bloodstream Infections: The Price of Anaerobic Coverage
Kolodyazhna, A., & Wiersinga, W. J. (2026) · Clinical Infectious Diseases · doi:10.1093/cid/ciag461
Ezaki, M., Noriko, K., Nagaoka, K., Yushi, M., Kazushige, S., Yusuke, K., Hounoki, H., Toru, W., Kawagishi, T., Naohiro, Y., et al. (2026) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2026.107953
Li, Y., Jin, S., & Tao, H. (2026) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2026.1823065
“Surgical failure rates exceed 30%, and recurrence is observed in more than 20% of cases (Li et al., 2025; Null, 2025).”
Botill, B., Bui, L., Collins, J., Hearing, A., & Guirguis, E. H. (2026) · The Senior Care Pharmacist · doi:10.4140/tcp.n.2026.198
Onorato, L., de Luca, I., Marika, F., Ricciardiello, G., Monari, C., & Coppola, N. (2026) · European Journal of Clinical Investigation · doi:10.1111/eci.70244
“Firstly, we decided to exclude from our analysis studies reporting a time to oral stepdown > 5 days, since several data have demonstrated that a total treatment of 7 days is non-inferior to longer duration in the management of uncomplicated Gram-negative bloodstream infections [23–25].”
Martín‐Loeches, I., Léone, M., Coopersmith, C. M., Machado, F. R., Hodgson, C. L., Calfee, C. S., & Schultz, M. J. (2026) · Intensive Care Medicine · doi:10.1007/s00134-026-08579-z · Cited by 1
Byskov, E. S., Pereira, L. G., Pirolo, M., Pedersen, K. S., Olsen, J. E., Guardabassi, L., & Damborg, P. (2026) · Porcine Health Management · doi:10.1186/s40813-026-00534-0
Shinohara, K., Tochitani, K., Katada, Y., Murata, T., Morita, M., Tsuda, Y., Tsuchido, Y., Yamamoto, M., Matsumura, Y., & Nagao, M. (2026) · Infection · doi:10.1007/s15010-026-02938-0 · Cited by 1
Mathers, A. (2026) · The Conversation · doi:10.64628/aai.5np65cmqm
Verbrugge, F. H., & van Diepen, S. (2026) · European Heart Journal Acute Cardiovascular Care · doi:10.1093/ehjacc/zuag120
Optimising the duration of antimicrobial treatment in the era of Antimicrobial Stewardship Programs
Rodríguez-Urbistondo, C., & Cisneros, J. M. (2026) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2026.107537
Anderson, M., Wong, L., & Lee, S. (2026) · Annals of Pharmacy Practice and Pharmacotherapy · doi:10.51847/jjdr89x8ly
Kim, D., Wright, E., & Moretti, L. (2024) · Annals of Pharmacy Practice and Pharmacotherapy · doi:10.51847/qokj1cthtt
Reddi, B. A. J. (2026) · Springer eBooks · doi:10.1007/978-3-032-31459-8_2
Roganović, J., & Roganović, V. (2026) · Antibiotics · doi:10.3390/antibiotics15090924
“More recently, the BALANCE group of investigators reported that seven days was non-inferior to fourteen days for blood-stream infections [12]; shorter-and longer-duration antibiotics show similar efficacy, with consistent effects observed across age groups and bacterial types [13].”
Larsson, E., Valadkhani, A., Eriksson, J., Svensk, E., Hammarskjöld, F., Castegren, M., Bentzer, P., Nielsen, N., Svennerholm, K., Eriksson, M., et al. (2026) · Acta Anaesthesiologica Scandinavica · doi:10.1111/aas.70339
Maraolo, A. E., Astorri, R., Cirillo, P., Granata, G., Emiliozzi, A., Tescione, M., Brigante, G., Cicalini, S., Petrosillo, N., Gentile, I., et al. (2026) · Microorganisms · doi:10.3390/microorganisms14102203
Naegele, S., Baik, B., Ravichandran, U., Shah, N. S., & Acree, M. E. (2026) · Antimicrobial Stewardship & Healthcare Epidemiology · doi:10.1017/ash.2026.10892
“4,5,7,8 For organisms producing extended spectrum beta-lactamase (ESBL) enzymes, piperacillin-tazobactam was not considered effective therapy.”
Shorter Antibiotic Duration for Pseudomonas Bacteremia: A Call for Future Trials
Albuquerque, A. M., Santolia, C. B., Zampieri, F. G., Brophy, J. M., & Lee, T. C. (2026) · Clinical Infectious Diseases · doi:10.1093/cid/ciag646
Pascale, R., Montironi, M., & Giannella, M. (2026) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000001242
Oral Fosfomycin for Complicated Urinary Tract Infection Remains a Murky Issue
Trautner, B. W., Cortes-Penfield, N. W., Gupta, K., Hirsch, E. B., & Lavergne, V. (2026) · Clinical Infectious Diseases · doi:10.1093/cid/ciag553
Koca, H., & Ayvat, P. U. (2026) · Infection · doi:10.1007/s15010-026-03019-y
THE PRESENCE OF PREOPERATIVE BACTEREMIA AND ITS IMPACT ON SURGICAL APPENDECTOMY OUTCOMES
McGuire, R. S., Grade, D. B., Borkovich, G. J., Pires, E. I. R., Orrison, R. T., Kupanoff, K. M., Weinberg, J. A., Bogert, J. N., & Soe-lin, H. (2026) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2026.117341
Metadata
- Authors
- The BALANCE Investigators
- Corresponding author
- The BALANCE Investigators
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2025-03-13
- Volume
- 392
- Issue
- 11
- Pages
- 1065-1078
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4404539334
- Cited by
- 158
- References
- 33
- Citations by year
- 2026: 80 · 2025: 76
- FWCI
- 48.21
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- Funders
- New Zealand Health Research Council
- Canadian Institutes of Health Research
- Physicians Services Incorporated Ontario
- Australian National Health Medical Research Council
- Physicians Services, by the Ontario Ministry of Health Alternate Funding Plan Innovation Fund
- Topics
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Keywords
- bloodstream infection, bacteremia, antibiotic duration, non-inferiority, mortality, intensive care unit patients, community-acquired infections, urinary tract infection
- MeSH terms
- Duration of Therapy, Adult, Aged, Aged, 80 and over, Anti-Bacterial Agents, Cross Infection, Drug Administration Schedule, Female, Humans, Intensive Care Units, Male, Middle Aged, Time Factors, Bacteremia, Treatment Outcome, Community-Acquired Infections, Kaplan-Meier Estimate, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.